NCT03033914 2026-02-17A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)Memorial Sloan Kettering Cancer CenterPhase 1/2 Active not recruiting82 enrolled
NCT02979522 2025-11-10A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin LymphomaTakedaPhase 1/2 Active not recruiting59 enrolled 63 charts